CA209-9KD Patient Summary
This is a clinical research study for men with metastatic prostate cancer (cancer that has spread) that no longer responds to treatments that lower testosterone.
The purpose of this study is to compare three different combination therapies, each containing a drug called nivolumab and another anti-cancer drug. All three combination therapies are considered investigational, which means that they are not currently approved to treat men with metastatic prostate cancer. The study doctors want to learn more about which therapy is most effective in treating metastatic prostate cancer.
This is an Open Label clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. Open Label means you will know which study drugs you are taking.
CA209-9KD is a phase 2 clinical research study that will include about 300 men. If you enroll, the length of time you will be involved in the study will depend on how your cancer responds to the study drug.
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.